Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PDLI

PDL BioPharma (PDLI) Stock Price, News & Analysis

PDL BioPharma logo

About PDL BioPharma Stock (NASDAQ:PDLI)

Key Stats

Today's Range
$2.47
$2.47
50-Day Range
$2.47
$2.47
52-Week Range
$2.09
$3.86
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
13.00
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PDLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PDL BioPharma and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PDLI Stock News Headlines

GT Biopharma Inc GTBP
Health Winners & Losers: Maxygen
Prepare for the “Mar-a-Lago Accord” Money Shock
Why Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for your money than tariffs is unfolding behind the scenes... Tucked inside this overlooked directive is a plan set to be executed for the first time in in U.S. history. One Stansberry Research's Senior Partner says it's set to trigger a rare window for potentially explosive gains in ONE asset immediately. (Not AI or crypto). Wall Street insiders are already positioning themselves... and he insists you should, too, before it's too late.tc pixel
PDLI Historical Data
ABVC - ABVC BioPharma, Inc.
RDHL - RedHill Biopharma Ltd.
LABP
See More Headlines

PDLI Stock Analysis - Frequently Asked Questions

PDL BioPharma, Inc. (NASDAQ:PDLI) posted its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported ($0.43) EPS for the quarter, missing the consensus estimate of $0.10 by $0.53. The biotechnology company had revenue of $5.21 million for the quarter.

Based on aggregate information from My MarketBeat watchlists, some other companies that PDL BioPharma investors own include AT&T (T), OPKO Health (OPK), Advanced Micro Devices (AMD), Canopy Growth (CGC), Novavax (NVAX), Pfizer (PFE) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
8/06/2020
Today
9/16/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:PDLI
CIK
882104
Employees
109
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
13.00
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Optionable
Beta
N/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:PDLI) was last updated on 9/16/2025 by MarketBeat.com Staff
From Our Partners